Labcorp (LH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Labcorp Holdings (LH) reported $3.53 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 9.5%. EPS of $4.35 for the same period compares to $3.94 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.49 billion, representing a surprise of +1.14%. The company delivered an EPS surprise of +5.07%, with the consensus EPS estimate being $4.14.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net book-to-bill Ratio ( TTM Book-to-Bill): 1.1% versus the two-analyst average estimate of 1.1%.Revenues- Biopharma Laboratory Services: $784.8 million compared to the $743.2 million average estimate based on four analysts. The reported number represents a change of +11% year over year.Revenues- Diagnostics Laboratories: $2.75 billion versus $2.74 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.Adjusted Operating Income- Diagnostics Laboratories: $482.8 million compared to the $466.41 million average estimate based on three analysts.Adjusted Operating Income- Biopharma Laboratory Services: $123.3 million versus the three-analyst average estimate of $117.62 million.Adjusted Operating Income- Unallocated corporate expense: $-74.5 million versus the two-analyst average estimate of $-78.99 million.View all Key Company Metrics for Labcorp here>>>Shares of Labcorp have returned -3.2% over the past month versus the Zacks S&P 500 composite's +5.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Labcorp Holdings Inc. (LH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks